CancerNCT05954299
Vincere Biobank Research Protocol
An observational study of Cancer, run by Vincere Cancer Center at 1 site in United States.
Trial summary
The Vincere Biobank aims to make quality biospecimens and associated clinical data available for research studies related to advancing medicine and improving care for patients, including cancer screening, treatment, and care. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cancer
- How many people
- 5,000 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Jul 2023to 31 Dec 2038
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adults age 18 years and older of any gender and demographic group, including both healthy participants and those with disease.
Who may be able to join
- 18 years of age or older; any gender
- Able to donate a blood, urine, tissue, and/or other biospecimen sample
- Able to provide informed consent to participate in the study
Who cannot join
- Minors, under the age of 18 years
- Individuals who lack the capacity to give informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Vincere Cancer Center
Scottsdale, Arizona, 85260
Christine Lau, MD, 480-306-5390, drlau@vincerecancer.com
Vershalee Shukla, MD
About this study
The Vincere Biobank aims to make quality biospecimens and associated clinical data available for research studies related to advancing medicine and improving care for patients, including cancer screening, treatment, and care.
- Conditions
- Cancer
- Keywords
- Cancer, Biobank, Biorepository
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Normal | Participants and donor samples without disease (ex: non-cancer) | |
| Disease state or condition | Participants and donor samples with known disease or condition (ex: cancer) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Biobank
Collect quality biospecimens with associated clinical data for research studies related to improving medicine and care to the patient, including cancer screening, treatment, and care.
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2023
- Study start18 Jul 2023
- Primary completion31 Dec 2033 (estimated)
- Study completion31 Dec 2038 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vincere Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Vershalee Shukla, MD, Principal investigator, Vincere Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05954299
- Sponsor's protocol ID
- VCC-BIOBANK-001
- Status last verified
- Dec 2023
- First submitted
- 12 Jul 2023
- Last updated
- 7 Dec 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vincere Biobank Research Protocol
- ClinicalTrials.gov ID
- NCT05954299
- Acronym / sponsor ID
- VCC-BIOBANK-001
- Conditions
- Cancer
- Keywords
- Cancer, Biobank, Biorepository
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- Vincere Cancer CenterUniversity, hospital or other
- Study start
- 18 Jul 2023 (actual)
- Primary completion
- 31 Dec 2033 (estimated)
- Study completion
- 31 Dec 2038 (estimated)
- First posted
- 20 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Vincere Biobank aims to make quality biospecimens and associated clinical data available for research studies related to advancing medicine and improving care for patients, including cancer screening, treatment, and care.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Normal | – | –Participants and donor samples without disease (ex: non-cancer) |
| Disease state or condition | – | –Participants and donor samples with known disease or condition (ex: cancer) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adults age 18 years and older of any gender and demographic group, including both healthy participants and those with disease.
Key inclusion criteria (3 listed)
- 18 years of age or older; any gender
- Able to donate a blood, urine, tissue, and/or other biospecimen sample
- Able to provide informed consent to participate in the study
Key exclusion criteria (2 listed)
- Minors, under the age of 18 years
- Individuals who lack the capacity to give informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Biobank
Time frame: 10 years
Collect quality biospecimens with associated clinical data for research studies related to improving medicine and care to the patient, including cancer screening, treatment, and care.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Dec 2023.
Related trials for Cancer
RecruitingPhase 2
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Not yet recruiting
Effect of a Health Belief Model Based Digital Nudge Intervention on Breast Cancer Screening
Breast Cancer Screening, Breast Cancer Awareness
Not yet recruiting
The AYA Oncology Self-care Movement
Acute Lymphobkastic Leukemia, Medication Adherence
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
RecruitingPhase 2
The COSMYC Trial (COmbined Suppression of MYC)
Metastatic Castration-resistant Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Vershalee Shukla, MD principal investigator
Vincere Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by Vincere Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Christine Lau, MD (480-306-5390, drlau@vincerecancer.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Biobank (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Dec 2023; AzTrials last refreshed its copy on 30 Oct 2026.